In Vitro Synergistic Effects of Hinokitiol and Fluconazole Against Candida albicans
Source abstract
Abstract
Background: Given the escalating resistance of Candida albicans biofilms to conventional antifungal agents, in this research, we evaluated the potential of combination therapy comprising hinokitiol (HNK) and fluconazole (FLZ), as an alternative, for combating biofilm-associated infections. Methods: To assess their synergistic effects, the fractional inhibitory concentration index was calculated. The viability of biofilms and intracellular oxidative stress were quantified by XTT and reactive oxygen species assays. Structural integrity and viability were further investigated by fluorescence and scanning electron microscopy; gene expression levels were measured by real-time fluorescence analysis. Results: Treatment with HNK combined with FLZ led to noticeable disruptions in the biofilm architecture of Candida albicans and resulted in significant modulation of multiple biofilm-associated genes, such as ALS3 and HWP1. The observed increase in oxidative stress, together with a marked decline in biofilm viability, provided strong support for a synergistic effect between the two compounds. Conclusions: The findings in this study revealed a potential synergistic effect between HNK and FLZ, with influences on fungal biofilm architecture and modulation of genetic pathways associated with biofilm development.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Antifungal resistance and susceptibility · Synthesis of Organic Compounds · Sinusitis and nasal conditions
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Dental Medicine, Kyoto Prefectural University of Medicine, Kamigyo, Kyoto 602-8566, Japan
Division of Creative and Integrated Medicine, Advanced Medicine Research Center, Translational Research Institute for Medical Innovation (TRIMI), Osaka Dental University, 8-1 Kuzuhahanazono-cho, Hirakata-shi, Osaka 573-1121, Japan
References (63)
Show source-provided references
1. Invasive candidiasis10.1038/s41572-024-00503-3 ↗
2. Epidemiology of invasive candidiasis: A persistent public health problem10.1128/CMR.00029-06 ↗
3. Microbe Profile: Candida albicans: A shape-changing, opportunistic pathogenic fungus of humans10.1099/mic.0.000499 ↗
4. Molecular evolution of antifungal drug resistance10.1146/annurev-micro-030117-020345 ↗
5. In vitro low-level resistance to azoles in Candida albicans is associated with changes in membrane lipid fluidity and asymmetry10.1128/AAC.46.4.1046-1052.2002 ↗
6. Drug discovery in pharmaceutical industry: Productivity challenges and trends10.1016/j.drudis.2012.05.007 ↗
7. Wang, C.H., Yu, J., Cai, Y.X., Zhu, P.P., Liu, C.Y., Zhao, A.C., Lü, R.H., Li, M.J., Xu, F.X., and Yu, M.D. (2016). Characterization and functional analysis of 4-coumarate: CoA ligase genes in mulberry. PLoS ONE, 11.10.1371/journal.pone.0157414 ↗
8. Tackling the emerging threat of antifungal resistance to human health10.1038/s41579-022-00720-1 ↗
9. Biofilms: Survival mechanisms of clinically relevant microorganisms10.1128/CMR.15.2.167-193.2002 ↗
10. Candida tropicalis biofilm’s matrix–involvement on its resistance to amphotericin B10.1016/j.diagmicrobio.2015.06.015 ↗
11. Mechanisms of Candida biofilm drug resistance10.2217/fmb.13.101 ↗
12. Antifungal drugs: What brings the future?10.1093/mmy/myz012 ↗
13. Synergistic drug combinations tend to improve therapeutically relevant selectivity10.1038/nbt.1549 ↗
14. Ahmad, A., Wani, M.Y., Khan, A., Manzoor, N., and Molepo, J. (2015). Synergistic interactions of eugenol-tosylate and its congeners with fluconazole against Candida albicans. PLoS ONE, 10.10.1371/journal.pone.0145053 ↗
15. A combination approach to treating fungal infections10.1038/srep17070 ↗
16. Apoptosis-linked antifungal effect of ambroxol hydrochloride by cystolic calcium concentration disturbance in resistant Candida albicans10.1007/s11427-018-9830-0 ↗
17. Aripiprazole repurposed as an inhibitor of biofilm formation and sterol biosynthesis in multidrug-resistant Candida albicans10.1016/j.ijantimicag.2019.05.016 ↗
18. Antifungal activity of ribavirin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence10.1016/j.ijantimicag.2019.09.008 ↗
19. Bersan, S.M., Galvao, L.C., Goes, V.F., Sartoratto, A., Figueira, G.M., Rehder, V.L., Alencar, S.M., Duarte, R.M., Rosalen, P.L., and Duarte, M.C. (2014). Action of essential oils from Brazilian native and exotic medicinal species on oral biofilms. BMC Complement. Altern. Med., 14.10.1186/1472-6882-14-451 ↗
20. Antifungal and anti-inflammatory potential of eschweilenol C-rich fraction derived from Terminalia fagifolia Mart10.1016/j.jep.2019.111941 ↗
21. Spilanthol as a promising antifungal alkylamide for the treatment of vulvovaginal candidiasis10.1093/mmy/myab054 ↗
22. Fungicidal activity of thymol and carvacrol by disrupting ergosterol biosynthesis and membrane integrity against Candida10.1007/s10096-010-1050-8 ↗
23. Antibiofilm activity of certain phytocompounds and their synergy with fluconazole against Candida albicans biofilms10.1093/jac/dkr512 ↗
24. Candida albicans biofilm inhibition by synergistic action of terpenes and fluconazole
25. Differential inhibitory effects of protoberberines on sterol and chitin biosyntheses in Candida albicans10.1093/jac/43.5.667 ↗
26. Proteomic analysis reveals a synergistic mechanism of fluconazole and berberine against fluconazole-resistant Candida albicans: Endogenous ROS augmentation10.1021/pr9005074 ↗
27. The combination of minocycline and fluconazole causes synergistic growth inhibition against Candida albicans: An in vitro interaction antifungal antibacterial agents10.1111/j.1567-1364.2010.00664.x ↗
28. Artemisinins, new fluconazole potentiators resulting in increased activity against Candida albicans biofilms10.1128/AAC.04229-14 ↗
29. Antimicrobial/antibiofilm activity and cytotoxic studies of b-thujaplicin derivatives10.1002/ardp.201600095 ↗
30. Kim, D.J., Lee, M.W., Choi, J.S., Lee, S.G., Park, J.Y., and Kim, S.W. (2017). Inhibitory activity of hinokitiol against biofilm formation in fluconazole-resistant Candida species. PLoS ONE, 12.10.1371/journal.pone.0171244 ↗
31. Investigation of antibacterial effects of hinokitiol on Lactobacillus casei
32. Investigation of antibacterial effects of hinokitiol on Fusobacterium nucleatum
33. Hinokitiol exhibits potent anticancer effects in human oral squamous cell carcinoma by inducing apoptosis and inhibition of cell migration10.1016/j.ajoms.2025.02.019 ↗
34. Vila, T., Sultan, A.S., Montelongo-Jauregui, D., and Jabra-Rizk, M.A. (2020). Oral candidiasis: A disease of opportunity. J. Fungi, 6.10.3390/jof6010015 ↗
35. Perić, M., Miličić, B., Kuzmanović Pfićer, J., Živković, R., and Arsić Arsenijević, V. (2024). A systematic review of denture stomatitis: Predisposing factors, clinical features, etiology, and global Candida spp. distribution. J. Fungi, 10.10.3390/jof10050328 ↗
36. A relationship between salivary flow rates and Candida counts in patients with xerostomia10.4103/jomfp.JOMFP_231_16 ↗
37. Exploring oral candidiasis among cancer patients undergoing chemotherapy in eastern Iran
38. A systematic review of oral fungal infections in medically compromised patients
39. Wu, Y., Du, S., Johnson, J.L., Tung, H.Y., Landers, C.T., Liu, Y., Seman, B.G., Wheeler, R.T., Costa-Mattioli, M., and Kheradmand, F. (2019). Microglia and amyloid precursor protein coordinate control of transient Candida cerebritis with memory deficitis. Nat. Commun., 58.10.1038/s41467-018-07991-4 ↗
40. Detection of microscopic filamentous fungal biofilms choosing the suitable methodology10.1016/j.mimet.2023.106676 ↗
41. Manoharan, R.K., Lee, J.H., Kim, Y.G., and Lee, J. (2017). Alizarin and chrysazin inhibit biofilm and hyphal formation by candida albicans. Front. Cell Infect. Microbiol., 7.10.3389/fcimb.2017.00447 ↗
42. XTT assay of ex vivo saliva biofilms to test antimicrobial influences
43. Phospholipase B enzyme expression is not associated with other virulence attributes in Candida albicans isolates from patients with human immunodeficiency virus infection10.1099/jmm.0.45762-0 ↗
44. Candida albicans HWP1 gene expression and host antibody responses in colonization and disease10.1099/jmm.0.46737-0 ↗
45. Characteristics of Candida albicans biofilms grown in a synthetic urine medium10.1128/JCM.01377-09 ↗
46. Atiencia-Carrera, M.B., Cabezas-Mera, F.S., Vizuete, K., Debut, A., Tejera, E., and MaChado, A. (2022). Evaluation of the biofilm life cycle between Candida albicans and Candida tropicalis. Front. Cell Infect. Microbiol., 12.10.3389/fcimb.2022.953168 ↗
47. Yu, J., Wang, F., Shen, Y., Yu, F., Qiu, L., Zhang, L., Chen, Y., Yuan, Q., Zhang, H., and Sun, Y. (2022). Inhibitory effect of ficin on Candida albicans biofilm formation and pre-formed biofilms. BMC Oral. Health, 22.10.1186/s12903-022-02384-y ↗
48. Zhu, J., Chu, W., Luo, J., Yang, J., He, L., and Li, J. (2022). Dental materials for oral microbiota dysbiosis: An update. Front. Cell Infect. Microbiol., 12.10.3389/fcimb.2022.900918 ↗
49. Atiencia-Carrera, M.B., Cabezas-Mera, F.S., Tejera, E., and MaChado, A. (2022). Prevalence of biofilms in Candida spp. bloodstream infections: A meta-analysis. PLoS ONE, 17.10.1371/journal.pone.0263522 ↗
50. I In Vitro antimicrobial and anticancer potential of hinokitiol against oral pathogens and oral cancer cell lines10.1016/j.micres.2012.12.007 ↗
51. Oxidative Stress Responses in the Human Fungal Pathogen, Candida albicans10.3390/biom5010142 ↗
52. (+)-Medioresinol leads to intracellular ROS accumulation and mitochondria-mediated apoptotic cell death in Candida albicans10.1016/j.biochi.2012.04.010 ↗
53. Efficient capture and T2 magnetic resonance assay of candida albicans with inorganic nanoparticles: Role of nanoparticle surface charge and fungal cell wall10.1021/acsbiomaterials.9b00069 ↗
54. D319 induced antifungal effects through ROS-mediated apoptosis and inhibited isocitrate lyase in Candida albicans10.1016/j.bbagen.2021.130050 ↗
55. Candida albicans ALS3, a multifunctional adhesin and invasion10.1128/EC.00279-10 ↗
56. ALS1 and ALS3 gene expression and biofilm formation in Candida albicans isolated from vulvovaginal candidiasis10.4103/2277-9175.183666 ↗
57. NRG1 represses yeast-hypha morphogenesis and hypha-specific gene expression in Candida albicans10.1093/emboj/20.17.4742 ↗
58. Differentiation of Candida albicans complex species isolated from invasive and non-invasive infections using HWP1 gene size polymorphism
59. Development of anti-virulence approaches for candidiasis via a novel series of small-molecule inhibitors of Candida albicans filamentation10.1128/mBio.01991-17 ↗
60. Candida albicans biofilm growth and dispersal: Contributions to pathogenesis10.1016/j.mib.2019.04.001 ↗
61. Pohl, C.H. (2022). Recent advances and opportunities in the study of candida albicans polymicrobial biofilms. Front. Cell Infect. Microbiol., 12.10.3389/fcimb.2022.836379 ↗
62. The regulation of hyphae growth in Candida albicans10.1080/21505594.2020.1748930 ↗
63. Molecular genetic techniques for gene manipulation in Candida albicans10.4161/viru.28893 ↗